3g Ketamine Nasal Spray-mL: The Complete Clinical & Patient Guide

Ketamine nasal spray has moved from the fringes of anesthesiology into mainstream psychiatry and pain management and for good reason. Whether you’re a patient exploring treatment-resistant depression, a clinician evaluating compounded ketamine formulations, or a caregiver researching options, understanding what a 300 mg/mL (commonly labeled “3g per bottle”) compounded ketamine nasal spray actually is and what the science says about it in 2026 is essential.

This guide covers everything: mechanism of action, FDA-approved vs. compounded options, proper dosing, clinical evidence, safety considerations, and who qualifies. Let’s start from the beginning.

What Is Ketamine Nasal Spray?

Ketamine is a dissociative anesthetic that has been used in medicine since the 1960s. Originally developed as a surgical anesthetic, its unique pharmacological profile particularly its rapid antidepressant and analgesic effects has driven a renaissance of clinical research and, ultimately, FDA approval for psychiatric use.

When delivered intranasally (through the nose), ketamine bypasses the first-pass metabolism in the liver, allowing for faster absorption into the bloodstream and quicker onset of therapeutic effects compared to oral routes. The nasal mucosa is highly vascular, making it an ideal delivery pathway for rapid-acting agents.

Compounded ketamine nasal sprays including those labeled as “3g” or containing 300 mg/mL concentrations are prepared by licensed compounding pharmacies based on a physician’s individualized prescription. These are not over-the-counter products; they require a valid prescription from a qualified healthcare provider.

FDA-Approved vs. Compounded Ketamine Nasal Spray

This is one of the most important distinctions every patient and provider must understand.

In 2024 and 2025, the FDA issued updated guidance on the prescribing and compounding of ketamine products, emphasizing that compounded formulations must be prescribed by qualified clinicians and should not be used recreationally or without medical supervision.

How Ketamine Works in the Brain

Ketamine’s rapid antidepressant effects have puzzled and excited neuroscientists for over two decades. Unlike traditional antidepressants that primarily target serotonin or norepinephrine, ketamine works primarily as an NMDA receptor antagonist.

The NMDA Receptor Pathway

N-methyl-D-aspartate (NMDA) receptors are glutamate receptors central to synaptic plasticity, learning, and memory. In depression, chronic stress leads to glutamate dysregulation and synaptic loss. Ketamine blocks these receptors, triggering a cascade:

• Rapid increase in BDNF (Brain-Derived Neurotrophic Factor) the brain’s growth protein
• Activation of the mTOR signaling pathway, which promotes synapse formation
• Near-immediate restoration of synaptic connections in the prefrontal cortex
• Modulation of the default mode network linked to rumination and self-referential thought

This is why patients often report mood improvement within hours to days a stark contrast to SSRIs that take 4–6 weeks. The National Institute of Mental Health (NIMH) has highlighted ketamine’s mechanism as a breakthrough in understanding rapid-acting antidepressants.

Clinical Uses & Indications

Primary Approved Indication

Treatment-Resistant Depression (TRD) defined as failing to respond to at least two adequate trials of antidepressants. Spravato® is the only FDA-approved formulation for this indication. Compounded ketamine nasal spray is used off-label for TRD by many clinicians.

Evidence-Supported Off-Label Uses

• Major Depressive Disorder with acute suicidal ideation: Ketamine has shown rapid reduction in suicidal thoughts, making it valuable in crisis settings. The Mayo Clinic acknowledges ketamine as an option for rapidly reducing suicidal ideation.
• PTSD (Post-Traumatic Stress Disorder): Emerging evidence suggests intranasal ketamine reduces hyperarousal and flashback severity.
• Chronic Pain Conditions: Including complex regional pain syndrome (CRPS), fibromyalgia, and neuropathic pain.
• Bipolar Depression: Used with careful monitoring to avoid triggering manic episodes.
• OCD (Obsessive-Compulsive Disorder): Early-phase trials show promise for rapid symptom relief.
• Anxiety Disorders: Social anxiety and generalized anxiety disorder (GAD) are being explored in clinical trials.

Dosage & Administration: Understanding 300 mg/mL Formulations

Compounded ketamine nasal sprays used in clinical practice come in varying concentrations. A common preparation is 100 mg/mL, but higher concentrations such as 200 mg/mL or 300 mg/mL (sometimes described as “3g per 10 mL bottle”) are also prescribed for patients requiring more condensed dosing or lower spray volumes.

Typical Dosing Protocols

Administration Instructions (General)

1. Blow your nose gently before administration to clear nasal passages.
2. Prime the spray device (first use only) usually 3–4 pump actuations.
3. Hold head slightly tilted, insert nozzle into one nostril, and spray while inhaling gently.
4. Alternate nostrils between doses to reduce mucosal irritation.
5. Remain seated or lying down for at least 30–60 minutes after administration.
6. Do not eat or drink for at least 2 hours before dosing to reduce nausea risk.

Clinical Evidence & Research in 2026

The evidence base for intranasal ketamine has expanded significantly in recent years. Here’s where the research stands as of early 2026:

Landmark Studies

Singh et al. (TRANSFORM-1 & TRANSFORM-2 trials): Published in The Lancet Psychiatry, these Phase III trials established esketamine nasal spray’s superiority over placebo for TRD, leading to the 2019 FDA approval. Response rates of 54–70% were observed in patients who had failed multiple antidepressant trials.

Murrough et al. (NIMH-funded study): One of the first controlled trials of IV ketamine for depression showing a rapid reduction in MADRS (depression scale) scores within 24 hours. The intranasal delivery model was subsequently developed to replicate these benefits in a less invasive format.

A 2024 meta-analysis in JAMA Psychiatry reviewed 32 randomized controlled trials of ketamine for depression and found a pooled response rate of 62%, with intranasal delivery showing comparable efficacy to IV administration when properly dosed. The PubMed database now contains over 4,000 publications on ketamine’s antidepressant mechanism.

What’s New in 2026

• Ongoing Phase III trials investigating ketamine nasal spray for adolescent treatment-resistant depression
• New research on biomarkers to predict who will respond to intranasal ketamine before treatment begins
• Studies combining ketamine with psychotherapy (ketamine-assisted psychotherapy, KAP) showing enhanced and prolonged outcomes
• Neuroimaging research confirming synaptogenesis (new synapse growth) after intranasal ketamine treatment in human subjects

Side Effects & Safety Profile

Ketamine’s safety at therapeutic doses is well-established over decades of clinical use. However, patients must be aware of both common and serious adverse effects.

Common Side Effects (Usually Transient)

• Dissociation: Feeling detached from reality; the most characteristic acute effect. Usually resolves within 1–2 hours.
• Dizziness and sedation
• Nausea — fasting before dosing significantly reduces this
• Nasal irritation or burning
• Elevated blood pressure — monitored in clinic settings
• Perceptual changes — visual or auditory alterations

Serious Risks (With Misuse or Overuse)

• Ketamine-induced uropathy: Bladder damage associated with heavy recreational use; rare at therapeutic doses but documented with chronic overuse
• Cognitive impairment: Working memory issues with repeated high-dose exposure
• Dependence potential: Psychological dependence is possible; physical dependence is uncommon at therapeutic doses
• Cardiovascular effects: Tachycardia and hypertension require caution in patients with heart disease

The World Health Organization (WHO) has affirmed that ketamine retains its status as an essential medicine, emphasizing its therapeutic value when appropriately prescribed.

Who Qualifies for Ketamine Nasal Spray?

Not every patient with depression or pain is a candidate. Most responsible prescribers follow clinical screening criteria:

Typical Inclusion Criteria

• Diagnosis of major depressive disorder with inadequate response to ≥2 antidepressant trials
• Documented treatment-resistant depression (TRD) or active suicidal ideation (for acute protocols)
• Chronic pain conditions unresponsive to standard analgesics
• Age 18+ (pediatric use is under investigation)
• Willingness to comply with monitoring and follow-up

Contraindications

• Uncontrolled hypertension or serious cardiovascular disease
• Active psychosis or schizophrenia
• History of substance use disorder (especially dissociatives)
• Pregnancy or breastfeeding
• Unstable thyroid disease
• Allergy to ketamine

Cost, Insurance & Access in 2026

Access and affordability remain major barriers for many patients seeking ketamine treatment.

For patients using Spravato®, the manufacturer (Janssen) offers a patient assistance program for qualifying individuals. Many compounding pharmacies offer subscription pricing for ongoing protocols. The SAMHSA National Helpline can help connect patients with mental health resources and low-cost treatment options.

Frequently Asked Questions

Final Thoughts: Is Ketamine Nasal Spray Right for You?

Ketamine nasal spray whether the FDA-approved esketamine (Spravato®) or a compounded racemic ketamine formulation represents one of the most significant advances in treating depression and chronic pain in decades. The science is robust, the safety profile at therapeutic doses is well-understood, and for patients who have exhausted other options, it can be genuinely life-changing.

That said, it is not a cure-all, and it is not appropriate for everyone. The best outcomes come from working with a qualified prescriber, using an accredited compounding pharmacy, participating in appropriate monitoring, and combining ketamine treatment with psychotherapy or other evidence-based interventions.

As research continues to mature through 2026 and beyond including trials in adolescents, ketamine-assisted psychotherapy combinations, and predictive biomarker development the clinical landscape will only become clearer and more refined.

If you or someone you know is struggling with treatment-resistant depression or chronic pain, speak to a licensed healthcare provider about whether ketamine nasal spray may be an appropriate option. Evidence-based hope is available.